RNA processing as an alternative route to attack glioblastoma

[1]  Fengqin Wang,et al.  Label-free quantitative proteomics unravels the importance of RNA processing in glioma malignancy , 2017, Neuroscience.

[2]  Jay-Jiguang Zhu,et al.  Metformin treatment reduces temozolomide resistance of glioblastoma cells , 2016, Oncotarget.

[3]  S. Agarwal,et al.  Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma , 2016, Genome Biology.

[4]  Robin T. Varghese,et al.  Survival kinase genes present prognostic significance in glioblastoma , 2016, Oncotarget.

[5]  Mihoko Kai.  Roles of RNA-Binding Proteins in DNA Damage Response , 2016, International journal of molecular sciences.

[6]  E. Chiocca,et al.  Therapeutic potential of targeting microRNA‐10b in established intracranial glioblastoma: first steps toward the clinic , 2016, EMBO molecular medicine.

[7]  S. Roman-Roman,et al.  Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage , 2016, Nature Communications.

[8]  C. Vogel,et al.  High-throughput analyses of hnRNP H1 dissects its multi-functional aspect , 2016, RNA biology.

[9]  M. Warmuth,et al.  Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.

[10]  S. Nelson,et al.  Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients , 2015, PloS one.

[11]  K. Gruden,et al.  Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance , 2015, Oncotarget.

[12]  S. Marie,et al.  Isolation and characterization of novel RECK tumor suppressor gene splice variants , 2015, Oncotarget.

[13]  Sarah J. Kurley,et al.  The spliceosome is a therapeutic vulnerability in MYC-driven cancer , 2015, Nature.

[14]  Denise M. Coley,et al.  The tumor suppressor HHEX inhibits axon growth when prematurely expressed in developing central nervous system neurons , 2015, Molecular and Cellular Neuroscience.

[15]  Jong Ho Park,et al.  Deleterious c-Cbl Exon Skipping Contributes to Human Glioma12 , 2015, Neoplasia.

[16]  E. Levanon,et al.  Identification of recurrent regulated alternative splicing events across human solid tumors , 2015, Nucleic acids research.

[17]  Henry W. Long,et al.  CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. , 2015, Cancer research.

[18]  G. Tedeschi,et al.  Suggestive evidence on the involvement of polypyrimidine-tract binding protein in regulating alternative splicing of MAP/microtubule affinity-regulating kinase 4 in glioma. , 2015, Cancer letters.

[19]  J. Phillips,et al.  Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells , 2015, PloS one.

[20]  Shawn M. Gomez,et al.  Transcriptome-wide identification and study of cancer-specific splicing events across multiple tumors , 2015, Oncotarget.

[21]  H. Ellis,et al.  Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma , 2015, Front. Oncol..

[22]  Caterina Marchiò,et al.  SF3B1 mutations constitute a novel therapeutic target in breast cancer , 2014, The Journal of pathology.

[23]  Sandeep Mittal,et al.  Targeting adaptive glioblastoma: an overview of proliferation and invasion. , 2014, Neuro-oncology.

[24]  P. Rogan,et al.  Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer , 2014, Scientific Reports.

[25]  H. Hamada,et al.  RBM14 prevents assembly of centriolar protein complexes and maintains mitotic spindle integrity , 2014, The EMBO journal.

[26]  F. Yu,et al.  Identification of differential splicing genes in gliomas using exon expression profiling , 2014, Molecular medicine reports.

[27]  C. Sander,et al.  Genome-wide analysis of non-coding regulatory mutations in cancer , 2014, Nature Genetics.

[28]  D. Scholtens,et al.  Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. , 2014, The Journal of clinical investigation.

[29]  G. Mezey,et al.  Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes , 2014, Journal of Cancer Research and Clinical Oncology.

[30]  M. Yaylaoglu,et al.  An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth , 2014, Genes & development.

[31]  Wei Li,et al.  CFIm25 links Alternative Polyadenylation to Glioblastoma Tumor Suppression , 2014, Nature.

[32]  Mihoko Kai,et al.  RNA binding protein RBM14 promotes radio-resistance in glioblastoma by regulating DNA repair and cell differentiation , 2014, Oncotarget.

[33]  Chandra Sekhar Pedamallu,et al.  A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.

[34]  S. Janga,et al.  Dissecting the expression landscape of RNA-binding proteins in human cancers , 2014, Genome Biology.

[35]  P. Taneja,et al.  AR-A 014418 Used against GSK3beta Downregulates Expression of hnRNPA1 and SF2/ASF Splicing Factors , 2014, Journal of oncology.

[36]  W. T. Beck,et al.  Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties , 2014, Oncogenesis.

[37]  Steven J. M. Jones,et al.  A Pan-Cancer Analysis of Alternative Splicing Events Reveals Novel Tumor-Associated Splice Variants of Matriptase , 2014, Cancer informatics.

[38]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[39]  Vishal N. Patel,et al.  Network Signatures of Survival in Glioblastoma Multiforme , 2013, PLoS Comput. Biol..

[40]  Yan-wei Liu,et al.  Whole‐Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme , 2013, CNS neuroscience & therapeutics.

[41]  F. J. Ramos,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[42]  Jen-Yang Tang,et al.  Modulating roles of amiloride in irradiation-induced antiproliferative effects in glioblastoma multiforme cells involving Akt phosphorylation and the alternative splicing of apoptotic genes. , 2013, DNA and cell biology.

[43]  Pablo R. Freire,et al.  Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. , 2013, Neuro-oncology.

[44]  Douglas L Black,et al.  EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. , 2013, Cell metabolism.

[45]  Emily J. Girard,et al.  Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. , 2013, Genes & development.

[46]  B. Lin,et al.  Alternative polyadenylation in glioblastoma multiforme and changes in predicted RNA binding protein profiles. , 2013, Omics : a journal of integrative biology.

[47]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[48]  L. C. Hinske,et al.  In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing , 2013, Acta Neuropathologica.

[49]  M. Cazzola,et al.  Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. , 2013, Blood.

[50]  Ahmed Sadeque,et al.  Identification and characterization of alternative exon usage linked glioblastoma multiforme survival , 2012, BMC Medical Genomics.

[51]  R. Krahe,et al.  PTBP1‐dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis , 2012, Molecular carcinogenesis.

[52]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[53]  M. Pajares,et al.  Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer , 2012, PloS one.

[54]  Richard J Jackson,et al.  Defining the roles and interactions of PTB. , 2012, Biochemical Society transactions.

[55]  F. Murad,et al.  Hydrogen Peroxide Alters Splicing of Soluble Guanylyl Cyclase and Selectively Modulates Expression of Splicing Regulators in Human Cancer Cells , 2012, PloS one.

[56]  Rui F. Oliveira,et al.  Face Your Fears: Cleaning Gobies Inspect Predators despite Being Stressed by Them , 2012, PloS one.

[57]  M. Gorospe,et al.  The Oncogenic RNA-Binding Protein Musashi1 Is Regulated by HuR via mRNA Translation and Stability in Glioblastoma Cells , 2012, Molecular Cancer Research.

[58]  C. Brennan,et al.  Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas , 2011, The EMBO journal.

[59]  Jianhua Ruan,et al.  Genomic Analyses of the RNA-binding Protein Hu Antigen R (HuR) Identify a Complex Network of Target Genes and Novel Characteristics of Its Binding Sites* , 2011, The Journal of Biological Chemistry.

[60]  N. Rajewsky,et al.  Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. , 2011, Molecular cell.

[61]  S. Srikantan,et al.  UneCLIPsing HuR nuclear function. , 2011, Molecular cell.

[62]  Uwe Ohler,et al.  Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. , 2011, Molecular cell.

[63]  Luigi Coppola,et al.  Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. , 2011, Cancer research.

[64]  P. Potter,et al.  Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. , 2011, ACS chemical biology.

[65]  N. Filippova,et al.  The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance , 2011, Molecular Cancer Research.

[66]  Kotb Abdelmohsen,et al.  Posttranscriptional regulation of cancer traits by HuR , 2010, Wiley interdisciplinary reviews. RNA.

[67]  S. Friedman,et al.  Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma , 2010, Clinical chemistry and laboratory medicine.

[68]  C. Vogel,et al.  A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue; identification of potential players in tumor formation , 2009, RNA biology.

[69]  F. Ali-Osman,et al.  A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. , 2009, Cancer research.

[70]  C. Mayr,et al.  Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer Cells , 2009, Cell.

[71]  J. Martignetti,et al.  The role of KLF6 and its splice variants in cancer therapy. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[72]  T. Waldman,et al.  Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme. , 2008, Cancer research.

[73]  R. Schiff,et al.  Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis. , 2008, Cancer research.

[74]  K. Baggerly,et al.  Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays , 2008, BMC Genomics.

[75]  W. Sly,et al.  Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas. , 2008, Neuro-oncology.

[76]  S. Friedman,et al.  Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma , 2007, International journal of cancer.

[77]  J. Coon,et al.  Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro , 2007, Oncogene.

[78]  D. Tuan,et al.  Gene amplification and associated loss of 5′ regulatory sequences of CoAA in human cancers , 2007, Oncogene.

[79]  N. Sharpless,et al.  The Regulation of INK4/ARF in Cancer and Aging , 2006, Cell.

[80]  U. Fischer,et al.  Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol , 2005, Clinical Cancer Research.

[81]  J. Schvartzman,et al.  Protein kinase clk/STY is differentially regulated during erythroleukemia cell differentiation: a bias toward the skipped splice variant characterizes postcommitment stages , 2005, Cell Research.

[82]  T. Yamori,et al.  Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107. Part 3. In vitro and in vivo Antitumor Activities. , 2004 .

[83]  H. Kawami,et al.  Identification of an Alternatively Spliced RNA for the Ras Suppressor RSU-1 in Human Gliomas , 2002, Journal of Neuro-Oncology.

[84]  Bert W O'Malley,et al.  Coordinate Regulation of Transcription and Splicing by Steroid Receptor Coregulators , 2002, Science.

[85]  J. Schramm,et al.  Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme , 2001, Acta Neuropathologica.

[86]  G. Fuller,et al.  Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. , 2000, Cancer research.

[87]  W. Jin,et al.  Glioblastoma cell-specific expression of fibroblast growth factor receptor-1beta requires an intronic repressor of RNA splicing. , 1999, Cancer research.

[88]  Kotb Abdelmohsen,et al.  Posttranslational control of HuR function , 2017, Wiley interdisciplinary reviews. RNA.

[89]  R. Verhaak,et al.  GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.

[90]  Gene W. Yeo.  RNA Processing Disease and Genome-wide Probing , 2016 .

[91]  J. Schramm,et al.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. , 2015, Neuro-oncology.

[92]  P. LoRusso,et al.  A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors , 2013, Investigational New Drugs.

[93]  Emily J. Girard,et al.  Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF 5 A , 2013 .

[94]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[95]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[96]  Xiuli Jiang,et al.  Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. , 2007, Cancer research.

[97]  G. Fuller,et al.  Expression of the splicing regulator polypyrimidine tract-binding protein in normal and neoplastic brain. , 2004, Neuro-oncology.

[98]  Teruyoshi Hishiki,et al.  BodyMap: a human and mouse gene expression database , 2000, Nucleic Acids Res..